Get the Stockscreener App
1.64
1.23%
0.02
60 Degrees Pharmaceuticals Inc stock is traded at $1.64, with a volume of 94,344.
It is up +1.23% in the last 24 hours and up +13.89% over the past month.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
See More
Previous Close:
$1.62
Open:
$1.57
24h Volume:
94,344
Relative Volume:
0.56
Market Cap:
$4.36M
Revenue:
$1.31M
Net Income/Loss:
$-7.56M
P/E Ratio:
-0.1593
EPS:
-10.2926
Net Cash Flow:
$-8.25M
1W Performance:
+18.84%
1M Performance:
+13.89%
6M Performance:
-51.16%
1Y Performance:
-81.02%
1-Day Range:
$1.57
$1.71
1-Week Range:
$1.35
$1.79
52-Week Range:
$1.22
$10.77
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Name
60 Degrees Pharmaceuticals Inc
Sector
Industry
Phone
202-327-5422
Address
1025 CONNECTICUT AVENUE NW, WASHINGTON
Compare SXTP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
1.64 | 4.36M | 1.31M | -7.56M | -8.25M | -10.29 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
60 Degrees Pharmaceuticals Inc Stock (SXTP) Latest News
Number of shareholders of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTPW - TradingView
60 Degrees Pharmaceuticals Inc (SXTP) Valuation: PE, PB & Fair Value Analysis - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
60 Degrees Pharmaceuticals Inc - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Institutional Confidence - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Valuation: PE, PB & Fair Value Analysis - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
60 Degrees Pharmaceuticals Inc (SXTPW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
60 Degrees Pharmaceuticals Inc (SXTP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Top Executive Makes Bold Move With Fresh Buy in Pharma Stock - TipRanks
Insider Buying: Geoffrey Dow Acquires Additional Shares of 60 De - GuruFocus
60 degrees pharmaceuticals CEO buys $10,131 in stock By Investing.com - Investing.com South Africa
60 degrees pharmaceuticals CEO buys $10,131 in stock - Investing.com
CEO Geoffrey Dow adds 7,350 SXTP shares in open-market buy - Stock Titan
60 Degrees Pharmaceuticals Licenses Patent to Produce Australian Chestnut Extract - marketscreener.com
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - The Manila Times
60 Degrees Pharmaceuticals Signs Exclusive Patent License - GlobeNewswire
Australian chestnut tree targeted for U.S. supplements in 60 Degrees Pharma deal - Stock Titan
60 Degrees Pharmaceuticals (SXTP) proposes 800K-share equity refresh, reverse split - Stock Titan
According to a document submitted to the U.S. Securities and Exchange Commission, the biopharmaceutical company 60 Degrees Pharmaceuticals, Inc. may submit a New Drug Application for its drug tafenoquine to the U.S. Food and Drug Administration bef - Bitget
60 Degrees details tafenoquine priority review voucher strategy - TipRanks
60 Degrees Pharmaceuticals to seek Priority Review Voucher if tafenoquine trial supports NDA - TradingView
60 Degrees Pharmaceuticals (SXTP) details potential NDA and FDA voucher path - Stock Titan
60 Degrees Pharmaceuticals Q1 2026 Earnings: EPS Falls Sharply Short of Estimates as Development Costs MountDebt Analysis Report - The Legal Advocate
SXTP Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseEarnings Revision Downgrade - newsline.com
SXTP Q1 2026 Earnings: Significant EPS Miss as Company Continues Pre-Revenue PhaseROE Trend Analysis - The Legal Advocate
60 Degrees Pharm 1Q Rev $162,000 >SXTP - Moomoo
60 Degrees Pharmaceuticals (SXTP) Slips 6% as Shares Test Key SupportNew Highs New Lows - newsline.com
60 Degrees Pharmaceuticals enrolls first patient in babesiosis trial - Investing.com
60 Degrees Pharmaceuticals enrolls first patient in babesiosis trial By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals Announces Early Enrollment of - GlobeNewswire
60 Degrees Pharmaceuticals Inc. (SXTP) Q1 2026 Earnings: EPS Misses Estimates, No Revenue YetFree Cash Flow Trends - The Legal Advocate
60 Degrees Pharma Nears FDA Deadline in Thin Holiday Trading - Bez Kabli
SXTP Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Operational ChallengesBuyback Announcement Report - The Legal Advocate
60 Degrees Pharmaceuticals (SXTP) Holds Near Support After Minor DeclineFlat Correction - Newser
60 Degrees Pharmaceuticals (SXTP) Dips 1.34% as Shares Test Support LevelSupport Level Bounce - Newser
60 Degrees Pharmaceuticals, Inc.Warrant (NQ: SXTPW - The Chronicle-Journal
SXTP Downgraded by HC Wainwright & Co. -- New Rating: Neutral - GuruFocus
60 Degrees Pharm Cut to Neutral From Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright Downgrades 60 Degrees Pharmaceuticals(SXTP.US) to Hold Rating - Moomoo
60 Degrees Pharmaceuticals (NASDAQ: SXTP) director files initial Form 3 insider report - Stock Titan
60 Degrees Pharmaceuticals appoints Eric Francois to board of directors By Investing.com - Investing.com Nigeria
60 Degrees Pharmaceuticals, Inc. Files Form 8-K with SEC – Company Details, NASDAQ Listing, and Compliance Highlights - Minichart
60 Degrees Pharmaceuticals appoints Eric Francois to board of directors - Investing.com
60 Degrees Pharmaceuticals appoints Eric Francois to board - TradingView
60 Degrees Pharmaceuticals Inc Stock (SXTP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):